Actively Recruiting
Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)
Led by University Health Network, Toronto · Updated on 2025-07-02
500
Participants Needed
1
Research Sites
253 weeks
Total Duration
On this page
Sponsors
U
University Health Network, Toronto
Lead Sponsor
P
Princess Margaret Hospital, Canada
Collaborating Sponsor
AI-Summary
What this Trial Is About
Patients who have undergone curative treatment may be at risk of relapse. This study will collect, annotate, and sequence biospecimens (blood, stool, and tissue) from patients across different tumor types to detect molecular residual disease (MRD) before metastases become radiographically or clinically detectable. This will allow for early cancer interception, and hopefully prolong relapse-free survival across tumor types.
CONDITIONS
Official Title
Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with histological confirmation of a solid tumor.
- Patients must have early stage or locally advanced disease that is planned for or have undergone curative treatment.
- Patient must be 65 18 years old.
- All patients must have signed and dated an informed consent form.
You will not qualify if you...
- None
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Princess Margaret Cancer Centre
Toronto, Ontario, Canada, M5G 2M9
Actively Recruiting
Research Team
C
Celeste Yu, MSc
CONTACT
E
Elizabeth Shah
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here